Found: 27
Select item for more details and to access through your institution.
Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019.
- Published in:
- JAMA Health Forum, 2022, v. 3, n. 5, p. e220888, doi. 10.1001/jamahealthforum.2022.0888
- By:
- Publication type:
- Article
Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry.
- Published in:
- Applied Health Economics & Health Policy, 2018, v. 16, n. 6, p. 753, doi. 10.1007/s40258-018-0417-3
- By:
- Publication type:
- Article
Pediatric Drugs, Accelerated Approval, and Prospects for Reform.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 1, p. 5, doi. 10.1007/s40272-023-00597-4
- By:
- Publication type:
- Article
Accelerated approval drug labels often lack information for clinical decision‐making.
- Published in:
- Pharmacotherapy, 2023, v. 43, n. 4, p. 300, doi. 10.1002/phar.2789
- By:
- Publication type:
- Article
Reducing Branded Prescription Drug Prices: A Review of Policy Options.
- Published in:
- Pharmacotherapy, 2017, v. 37, n. 11, p. 1469, doi. 10.1002/phar.2013
- By:
- Publication type:
- Article
The Role of Place in Person‐ and Family‐Oriented Long‐Term Services and Supports.
- Published in:
- Milbank Quarterly, 2023, v. 101, n. 4, p. 1076, doi. 10.1111/1468-0009.12664
- By:
- Publication type:
- Article
Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.
- Published in:
- Journal of Law, Medicine & Ethics, 2022, v. 50, p. 32, doi. 10.1017/jme.2022.33
- By:
- Publication type:
- Article
Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic.
- Published in:
- Journal of Law, Medicine & Ethics, 2022, v. 50, p. 8, doi. 10.1017/jme.2022.30
- By:
- Publication type:
- Article
Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019.
- Published in:
- JAMA Network Open, 2021, v. 4, n. 1, p. e2034890, doi. 10.1001/jamanetworkopen.2020.34890
- By:
- Publication type:
- Article
Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
- Published in:
- JAMA Network Open, 2020, v. 3, n. 11, p. e2023677, doi. 10.1001/jamanetworkopen.2020.23677
- By:
- Publication type:
- Article
Medicare Spending on Drugs With Accelerated Approval.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Effectiveness of artificial intelligence vs. human coaching in diabetes prevention: a study protocol for a randomized controlled trial.
- Published in:
- Trials, 2024, v. 25, p. 1, doi. 10.1186/s13063-024-08177-8
- By:
- Publication type:
- Article
Branded prescription drug spending: a framework to evaluate policy options.
- Published in:
- Journal of Pharmaceutical Policy & Practice, 2017, v. 10, p. 1, doi. 10.1186/s40545-017-0115-9
- By:
- Publication type:
- Article
Cost‐effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin‐exacerbated respiratory disease.
- Published in:
- International Forum of Allergy & Rhinology, 2021, v. 11, n. 12, p. 1626, doi. 10.1002/alr.22865
- By:
- Publication type:
- Article
Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.
- Published in:
- PLoS ONE, 2019, v. 14, n. 11, p. 1, doi. 10.1371/journal.pone.0225109
- By:
- Publication type:
- Article
The Association Between Drug Approvals and Burden of Disease From 1990 to 2017.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 3, p. e221117, doi. 10.1001/jamanetworkopen.2022.1117
- By:
- Publication type:
- Article
Affording Genetic Therapies in the Medicaid Program.
- Published in:
- 2020
- By:
- Publication type:
- Opinion
Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?
- Published in:
- Health Economics Review, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13561-022-00384-w
- By:
- Publication type:
- Article
Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?
- Published in:
- Health Economics Review, 2022, v. 12, p. 1, doi. 10.1186/s13561-022-00384-w
- By:
- Publication type:
- Article
Cost-effectiveness of School Hearing Screening Programs: A Scoping Review.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19.
- Published in:
- BMC Public Health, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12889-022-14148-y
- By:
- Publication type:
- Article
Anticipating Reforms to the Prescription Drug User Fees Act.
- Published in:
- 2022
- By:
- Publication type:
- Opinion
Examining Opportunities to Increase Savings From Medicare Price Negotiations.
- Published in:
- JAMA Internal Medicine, 2023, v. 183, n. 6, p. 581, doi. 10.1001/jamainternmed.2023.0763
- By:
- Publication type:
- Article
Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model.
- Published in:
- Addiction, 2022, v. 117, n. 4, p. 969, doi. 10.1111/add.15698
- By:
- Publication type:
- Article
Bridging the Silos of Service Delivery for High-Need, High-Cost Individuals.
- Published in:
- Population Health Management, 2016, v. 19, n. 6, p. 421, doi. 10.1089/pop.2015.0147
- By:
- Publication type:
- Article